Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations

Drugs

Volumn 53, Issue 5, 1997, Pages 736-751

  Nurmohamed, Michael T ^a,b   Ten Cate, Hugo ^a,b   Ten Cate, Jan W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; RECOMBINANT ERYTHROPOIETIN; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; GENERAL SURGERY; HEART INFARCTION; HEMODIALYSIS; HEMOSTASIS; HOME CARE; HUMAN; HYPOALDOSTERONISM; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; META ANALYSIS; NEUROSURGERY; NONHUMAN; ORAL DRUG ADMINISTRATION; ORTHOPEDIC SURGERY; OSTEOPOROSIS; POSTOPERATIVE THROMBOSIS; PREGNANCY; REVIEW; SKIN DISEASE; SPINAL CORD INJURY; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANGINA; ANIMALIA;

EID: 0030942567     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753050-00002     Document Type: Review

References (107)

1. Casu B. Structure and biological activity of heparin. Adv Carb Chem Biochem 1985; 43: 51-134
2. Tobelem G. Interactions between glycosaminoglycans and endothelial cells. In: Bounameaux H, editor. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker Inc. 1994; 129-42
3. Maclean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-7
4. Crafoord C. Preliminary report on postoperative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937; 79: 407-26
5. Albidgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Stand J Clin Lab Invest 1968; 21: 89-91
6. Choay J, Petitou M, Lormeau JC, et al. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9
7. Casu B, Oreste P, Torri G, et al. The structure of heparin oligosaccharide fragments with high anti-factor Xa activity containing the minimal antithrombin III-binding sequence. Biochem J 1981; 197: 599-609
8. Lindahl U, Thunberg L, Bäckström G, et al. Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 1984; 259: 12368-76
9. Fernandez F, Nguyen P, van Ryn J, et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-5
10. Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
11. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 975-83
12. Messmore HL, Griffin Jr B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Scien 1989; 556: 217-33
13. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45
14. Ockelford PA, Carter CJ, Cerskus A, et al. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb Res 1982; 27: 679-90
15. Verstraete M. Prophylaxis of venous thromboembolism. BMJ 1997 Jan 11; 314: 123-5
16. Barrowcliffe TW. Low molecular weight heparins. Br J Haematol 1995; 90: 1-7
17. Carter C, Gent M, Leclerc JR. The epidemiology of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia (PA): JB Lippincott Co, 1987: 1185-98
18. National Institute of Health Consensus Development Conference, JAMA 1986; 256: 744-9
19. Planes A, Vochelle N, Darmon JY, et al. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348 (2): 224-8
20. Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomized clinical trials. Lancet 1986; II: 143-6
21. Clagett GP, Reiss JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-40
22. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988: 1162-73
23. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40: 498-530
24. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular weight heparin in general and orthopedic surgery: a meta-analysis. Lancet 1992 Jul 18; 340 (8812): 152-6
25. Leizorovicz A, Haugh MC, Chapuis F-R, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20
26. Kakkar VJ, Cohen AT, Edmonson RA, et al. Low molecular weight heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341 (1); 259-65
27. Nurmohamed MT, Verhaeghe R, Haas S, et al. Comparative trial of a low molecular weight heparin (enoxaparin) for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995; 169: 567-71
28. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501
29. Jørgensen LN, Wille-Jørgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704
30. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995; 155: 366-72
31. Pineo GF, Hull RD. Prevention and treatment of venous thromboembolism. Drugs 1996; 52 (1): 71-92
32. Palareti G, Borghi B, Coccheri S, et al. Postoperative versus preoperative initiation of deep vein thrombosis prophylaxis with a low-molecular-weight heparin (nadroparin) in elective hip surgery. Clin Appl Thromb Haemostas 1996; 2: 18-24
33. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348 (2): 224-8
34. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weighl heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700
35. Bachmann F, Leyvraz PF. Low molecular weight heparins for prevention of venous thromboembolism following orthopedic surgery. In: Bounameaux H, ed. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker Inc, 1994: 187-212
36. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a randomized double-blind trial comparing a low molecular wight heparin fragment (enoxaparin) to placebo. Thromb Haemostas 1992; 67: 417-23
37. Hull R, Raskob G, Pineo G, et al. Acomparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6
38. The RD Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994; 76: 1174-85
39. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. Ann Intern Med 1996; 124: 619-26
40. Levine MN, Gent M, Hirsh J. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. Arch Intern Med 1996; 156: 851-6
41. Nurmohamed MT, van Riel AM, Henkens CMA, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemostas 1996; 75: 233-8
42. Turpie AGC. Low molecular weight heparins and heparinoids for prevention of venous thrombo-embolism in stroke and neurosurgical patients. In: Bounameaux H, editor. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker Inc, 1994; 213-23
43. Prins MH, Gelsema R, Sing AK, et al. Prophylaxis of deep venous thrombosis with a low-molecular weight heparin (Kabi/Fragmin) in stroke patients. Haemostas 1989; 19: 245-50
44. Sandset PM, Dahl T, Stiris M, et al. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep venous thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990; 16: 25-33
45. Turpie AGG, Hirsh J, Jay RM, et al. Double-blind randomized trial of Org 10172 low-molecular weight heparinoid in prevention of deep venous thrombosis in thrombotic stroke. Lancet 1987 Mar 7; I (8532): 523-6
46. Turpie AGG, Gent M, Côte R, et al. A low molecular weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann Intern Med 1992; 117: 353-7
47. Myllynen P, Kammonen M, Rokkanen P, et al. Deep venous thrombosis and pulmonary embolism in patients with acute spinal cord injury. A comparison with non-paralysed patients immobilized due to spinal fractures. J Trauma 1985; 25: 541-6
48. Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990; 113: 571-4
49. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-7
50. Samama MM, Gerotziafas GT. Low-molecular-weight heparins for prevention of venous thromboembolism in medical patients. In: Bounameaux H, editor. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker Inc, 1994: 225-40
51. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996; 26: 127-39
52. Ware JA, Salzman EW. Use of heparin in treatment of thromboembolic disorders. In: Lane DA, Lindahl U, editors. Heparin: Chemical and biological disorders, clinical applications. London: Edward Arnold, 1989: 475-94
53. Hirsh J, Marder VJ, Salzman et al. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder, editors. Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: J.B. Lippincott, 1987: 1266-72
54. Brandjes DPM, Heyboer H, Büller BR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1455-9
55. Hommes DW, Bura A, Mazzolai L, et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116: 279-84
56. Leizorovicz A, Simonneau G, Decousus H, et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. BMJ 1994; 309: 299-304
57. Lensing AWA, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low molecular weight heparins. Arch Intern Med 1995; 155: 601-7
58. Hirsh J, Siragusa S, Cosmi B, et al. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemostas 1995; 74: 360-3
59. Siragusa S, Cosmi B, Piovell F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996; 100: 269-77
60. Green D, Hull RD, Brant R, et al. Lower mortality in cancer patients treated with low-molecular-weight heparin versus standard heparin [letter]. Lancet 1992 Jun 13; 339 (8807): 1476
61. Norrby K, Ostergaard P. Basic-fibroblast-growth-factor mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirculation 1996; 16: 8-15
62. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-87
63. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81
64. Théry C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary emholism: a dose-ranging study. Circulation 1992; 85: 1380-9
65. Kuijer PMM, Gallus AS, Cade JF, et al. Randomized comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism [abstract]. Thromb Haemostas 1995; 73: 974
66. Meyer G, Grenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemostas 1995; 74: 1432-5
67. Simonneua G, Sors H, Charbonnier B, et al. Once daily low molecular weight heparin (LMWH) Tinzaparin versus unfractionated heparin (UFH) in the treatment of pulmonary embolism [abstract]. In: 14th International Congress on Thrombosis: 1996 Oct 14-19, Montpellier, France. Haemostasis 1996; 26 Suppl. 3: 003
68. Simonneua G, Sors H, Charbonnier B, et al. Once daily low molecular weight heparin (LMWH) Tinzaparin versus unfractionated heparin (UFH) in the treatment of pulmonary embolism [abstract]. In: 14th International Congress on Thrombosis: 1996 Oct 14-19, Montpellier, France. Haemostasis 1996; 26 Suppl. 3: 003
69. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism [abstract]. American Society of Hematology: Thirty-Eighth Annual Meeting 1996 Dec 6-10, Orlando (FL). Blood 1996 Nov 15; 88 (1 Suppl. Pt I): 626a
70. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism [abstract]. American Society of Hematology: Thirty-Eighth Annual Meeting 1996 Dec 6-10, Orlando (FL). Blood 1996 Nov 15; 88 (1 Suppl. Pt I): 626a
71. Nurmohamed MT, Büller HR, ten Cate JW. Low molecular weight heparins in extracorporeal circuits. In: Bounameaux H, editor. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: Marcel Dekker Inc. ,1994; 247-71
72. Massonnet-Castcl S. Pelissier E, Bara I, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16: 139-46
73. Demers C, Ginsberg JS. Deep venous thrombosis and pulmonary embolism in pregnancy. Clin Chest Med 1992; 13: 645-56
74. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for health care professionals. Circulation 1996; 93: 2212-45
75. Schneider D, Heilmann L, Harenberg J. Zur Plazentagängigkeit von niedermolekularem Heparin. Geburtsh Frauenheilk 1995; 55: 93-8
76. Rasmussen C, Wadt J, Jacobsen B. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int J Gynecol Obstet 1994; 47: 121-5
77. Dulitzki M, Pauzner R, Langevitz P, et al. Low-molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87: 380-3
78. Boda Z, Laszlo P, Retj̃o L, et al. Low molecular weight heparin and thromboprophylaxis in familial thrombophilia during the whole period of pregnancy [letter]. Thromb Haemostas 1996; 26: 128
79. Hunt JB, Doughty HA, Majumbar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemostas 1997 Jan: 77: 39-43
80. McDonald MM, Hataway WE. Anticoagulant therapy by continuous heparinization in newborn and older infants. J Pediatr 1982; 101: 451-7
81. Schlegel N, Macher MA, Hurtaud et al. The use of CY 216 in paediatric haemodialysis. In: Breddin K, Fareed J, Samama M, editors. Fraxiparine, First International Symposium. Stuttgart: Schattauer. 1989: 177-86
82. Fijnvandraat K, Nurmohamed MT, Peters M, et al. A cross-over dose finding study investigating a low molecular weight heparin (Fragmin) in six children on chronic hemodialysis [abstract]. Thromb Haemost 1993; 69: 649
83. Van Biljon I, Van Damme-Lombaerts R, Demol A, et al. Low molecular weight heparin for anticoagulation during haemodialysis in children: a preliminary study [letter]. Eur J Pediat 1996; 155: 70
84. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular weight heparin in pediatric patients with thrombotic disease: a dose ranging study. J Pediatr 1996; 128: 313-8
85. Massey EW, Biller J, Davis JN, et al. Large-dose infusions of heparinoid Org 10172 in ischemic stroke. Stroke 1990; 1289-92
86. Kay R, Wong KS, Woo J. Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke. Stroke 1994; 25: 684-5
87. Kay R, Wong KS, Yu YL, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-93
88. Major ongoing stroke trials. Trial of Org 10172 in acute treatment (TOAST). Stroke 1996; 27: 1933
89. Talley JD. Progress in interventional cardiology. J Interven Cardiol 1992; 5: 245-51
90. Amann FW, Neuenschwander CH, Meyer BJ. Fraxiparin for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost 1993; 19 Suppl. 1: 160-3
91. Melandri G, Semprinin F, Cervi V, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation 1993: 88: 2517-23
92. Gurfunkel EP, Manos EJ, Mejaíl RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Amer Coll Cardiol 1995; 26: 313-8
93. FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996 Mar 2; 347 (9001): 561-8
94. Glick A, Kornowski R, Michowich, et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 145-8
95. Ten Cate H, Henny CP, Büller HR, et al. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol 1984; 15: 268-70
96. Van Ryn-McKenna J, Cai L, Ofosu FA, et al. Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63: 271-4
97. Stiekema JCJ, Wijnand HP, ten Cate H, et al. Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan® (Org 10172) by protamine chloride. Thromb Res 1991; 63: 157-67
98. Salzman EW, Hirsh J, Marder VJ. Clinical use of heparin. In: Colman RW, Hirsh J, Marder VM, et al, editors. Hemostasis and thrombosis: Basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott Company. 1994; 1585-91
99. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994; 89: 1449-68
100. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
101. Aster RH. Heparin induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332: 1374-6
102. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-9
103. Slocum MM, Adams JG, Tewl R, et al. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 1996; 23: 839-43
104. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 1993; 70: 554-61
105. Dahlman T, Lindvall N, Hellgren M. Ostopenia in pregnancy during long-term heparin treatment: A radiological study post-partum. Br J Obstet Gynaecol 1990; 97: 221-8
106. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin®) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemostas 1994; 71: 7-11
107. Sivakumaran M, Ghosh K, Zaidi Y, et al. Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. Clin Lab Haematol 1996; 18: 55-7